These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33598084)

  • 81. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome.
    Erman H; Beydogan E; Cetin SI; Boyuk B
    Mediators Inflamm; 2020; 2020():3534042. PubMed ID: 32317862
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies].
    Nosov AE; Zenina MT; Gorbushina OY; Baidina AS; Vlasova EM; Alekseev VB
    Ter Arkh; 2021 Aug; 93(8):883-889. PubMed ID: 36286882
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?
    Almobarak AO; Barakat S; Suliman EA; Elmadhoun WM; Mohamed NA; Abobaker IO; Noor SK; Bushara SO; Ahmed MH
    Arab J Gastroenterol; 2015 Jun; 16(2):54-8. PubMed ID: 26174761
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens.
    Busca C; Sánchez-Conde M; Rico M; Rosas M; Valencia E; Moreno A; Moreno V; Martín-Carbonero L; Moreno S; Pérez-Valero I; Bernardino JI; Arribas JR; González J; Olveira A; Castillo P; Abadía M; Guerra L; Mendez C; Montes ML
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac279. PubMed ID: 35873289
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Assessment of hepatic steatosis algorithms in non-alcoholic fatty liver disease.
    Eremić-Kojić N; Đerić M; Govorčin ML; Balać D; Kresoja M; Kojić-Damjanov S
    Hippokratia; 2018; 22(1):10-16. PubMed ID: 31213752
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years.
    Lee HW; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
    J Diabetes Complications; 2021 Jan; 35(1):107747. PubMed ID: 33616043
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.
    Mansour A; Mohajeri-Tehrani MR; Samadi M; Gerami H; Qorbani M; Bellissimo N; Poustchi H; Hekmatdoost A
    Acta Diabetol; 2019 Nov; 56(11):1199-1207. PubMed ID: 31197470
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease.
    Baeg MK; Yoon SK; Ko SH; Noh YS; Lee IS; Choi MG
    World J Gastroenterol; 2016 Feb; 22(8):2592-600. PubMed ID: 26937147
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
    Lomonaco R; Bril F; Portillo-Sanchez P; Ortiz-Lopez C; Orsak B; Biernacki D; Lo M; Suman A; Weber MH; Cusi K
    Diabetes Care; 2016 Apr; 39(4):632-8. PubMed ID: 26861926
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Ultrasound- and biomarker-based assessment of hepatic steatosis in patients with severe obesity.
    Byra M; Szmigielski C; Kalinowski P; Paluszkiewicz R; Ziarkiewicz-Wróblewska B; Zieniewicz K; Styczyński G
    Pol Arch Intern Med; 2023 Jan; 133(1):. PubMed ID: 36098578
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis.
    Carvalho JA; Barengo NC; Tuomilehto J; Conceição RD; Santos RD
    Ann Med; 2011; 43(6):487-94. PubMed ID: 21604917
    [TBL] [Abstract][Full Text] [Related]  

  • 94. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy.
    Bettini S; Bordigato E; Milan G; Dal Pra' C; Favaretto F; Belligoli A; Sanna M; Serra R; Foletto M; Prevedello L; Busetto L; Fassina G; Vettor R; Fabris R
    Obes Facts; 2019; 12(3):291-306. PubMed ID: 31104052
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A clinically relevant method to screen for hepatic steatosis in overweight adolescents: a cross sectional study.
    Saad V; Wicklow B; Wittmeier K; Hay J; MacIntosh A; Venugopal N; Ryner L; Berard L; McGavock J
    BMC Pediatr; 2015 Oct; 15():151. PubMed ID: 26450572
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease.
    Esteghamati A; Noshad S; Khalilzadeh O; Khalili M; Zandieh A; Nakhjavani M
    Metab Syndr Relat Disord; 2011 Apr; 9(2):111-7. PubMed ID: 21091060
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics.
    Haentjens P; Massaad D; Reynaert H; Peeters E; Van Meerhaeghe A; Vinken S; Poppe K; Velkeniers B
    Acta Clin Belg; 2009; 64(6):483-93. PubMed ID: 20101871
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Predictive Ability of Hepatic Steatosis Index for Gestational Diabetes Mellitus and Large for Gestational Age Infant Compared with Other Noninvasive Indices Among Chinese Pregnancies: A Preliminary Double-center Cohort Study.
    Song S; Duo Y; Zhang Y; Qiao X; Xu J; Zhang J; Peng Z; Chen Y; Nie X; Sun Q; Yang X; Wang A; Sun W; Fu Y; Dong Y; Lu Z; Yuan T; Zhao W
    Diabetes Metab Syndr Obes; 2021; 14():4791-4800. PubMed ID: 34938090
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.
    Leite NC; Salles GF; Araujo AL; Villela-Nogueira CA; Cardoso CR
    Liver Int; 2009 Jan; 29(1):113-9. PubMed ID: 18384521
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
    Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
    Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.